Castle Biosciences Announces New York State Department of Health Approval of Its TissueCypher Barretts Esophagus Test
CSTL Stock | USD 28.22 0.73 2.66% |
About 56% of all Castle Biosciences' institutional investors are looking to take a long position. The analysis of the overall investor sentiment regarding Castle Biosciences suggests that some traders are interested. Castle Biosciences' investing sentiment shows overall attitude of investors towards Castle Biosciences.
Castle |
Castle Biosciences has received assay approval from the New York State Department of Health for its TissueCypher Barretts Esophagus test.
Read at businesswire.com
Castle Biosciences Fundamental Analysis
We analyze Castle Biosciences' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Castle Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Castle Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Price To Sales
Price To Sales Comparative Analysis
Castle Biosciences is currently under evaluation in price to sales category among its peers. Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
Castle Biosciences Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Castle Biosciences stock to make a market-neutral strategy. Peer analysis of Castle Biosciences could also be used in its relative valuation, which is a method of valuing Castle Biosciences by comparing valuation metrics with similar companies.
Peers
Castle Biosciences Related Equities
PSNL | Personalis | 6.99 | ||||
STIM | Neuronetics | 6.56 | ||||
SERA | Sera Prognostics | 5.72 | ||||
GH | Guardant Health | 4.81 | ||||
NTRA | Natera | 4.79 | ||||
BNR | Burning Rock | 3.35 | ||||
TWST | Twist Bioscience | 3.27 | ||||
CDNA | Caredx | 1.86 | ||||
XGN | Exagen | 0.25 | ||||
BDSX | Biodesix | 0.95 | ||||
FONR | Fonar | 2.04 | ||||
ENZ | Enzo Biochem | 4.76 |
Check out Castle Biosciences Hype Analysis, Castle Biosciences Correlation and Castle Biosciences Performance. For more information on how to buy Castle Stock please use our How to buy in Castle Stock guide.You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Castle Biosciences. If investors know Castle will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Castle Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Castle Biosciences is measured differently than its book value, which is the value of Castle that is recorded on the company's balance sheet. Investors also form their own opinion of Castle Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Castle Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Castle Biosciences' market value can be influenced by many factors that don't directly affect Castle Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Castle Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Castle Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Castle Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.